Last $38.26 USD
Change Today -0.63 / -1.62%
Volume 247.1K
CMRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

chimerix inc (CMRX) Snapshot

Open
$38.74
Previous Close
$38.89
Day High
$39.02
Day Low
$37.92
52 Week High
01/5/15 - $42.87
52 Week Low
05/20/14 - $14.02
Market Cap
1.6B
Average Volume 10 Days
476.8K
EPS TTM
$-1.56
Shares Outstanding
40.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHIMERIX INC (CMRX)

chimerix inc (CMRX) Related Businessweek News

View More BusinessWeek News

chimerix inc (CMRX) Details

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

67 Employees
Last Reported Date: 11/7/14
Founded in 2000

chimerix inc (CMRX) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $340.0K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2013.

chimerix inc (CMRX) Key Developments

Chimerix, Inc. Provides Update on Brincidofovir Pivotal Phase 3 Advise Trial for the Treatment of Adenovirus

Chimerix, Inc. provided an update on AdVise, a Phase 3 trial of brincidofovir for the treatment of adenovirus, an infection that can be fatal in people with weakened immune systems. There are currently no approved treatments for adenovirus. The AdVise trial is enrolling immunocompromised individuals - including allogeneic hematopoietic cell transplant (HCT, or bone marrow transplant) recipients, solid organ transplant recipients and people who are immunosuppressed following chemotherapy. In the planned final study design, patients will receive brincidofovir twice weekly for 12 weeks, with a 12-week follow-up period. Since there are no other treatments for adenovirus, the 24-week survival of each brincidofovir-treated patient will be compared to two historic controls; matched historic controls will be selected from the same participating medical centers, and will include patients with confirmed adenovirus infection who received supportive care and best available therapy prior to the initiation of AdVise. The controls will be matched by cohort (i.e., allogeneic HCT with or without disseminated disease), age, and transplant type. Data from the pilot portion of the AdVise study that was initiated in March 2014 will also be part of the final data analysis. Brincidofovir for the Treatment of Ebola Virus Disease: A Phase 2 open-label study evaluating brincidofovir in up to 140 patients with confirmed Ebola Virus Disease was initiated on January 2 at Médecins Sans Frontières (MSF)'s ELWA 3 Ebola Management Centre in Monrovia, Liberia. The clinical evaluation is being conducted through a collaboration with the University of Oxford and the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) with operational support from MSF and funding provided by The Wellcome Trust. Discussions are ongoing regarding randomized clinical trials of brincidofovir for Ebola Virus Disease.

Chimerix, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 10:00 AM

Chimerix, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: M. Michelle Berrey, Chief Executive Officer, President, Chief Medical Officer and Director.

Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157

Chimerix, Inc. and ContraVir Pharmaceuticals, Inc. announced that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. CMX157 is a highly potent analog of the successful antiviral drug tenofovir DF (Viread). Under the agreement, ContraVir licenses CMX157 from Chimerix in exchange for an upfront payment consisting of 120,000 shares of ContraVir preferred stock with a stated value of $1.2 million. In addition, Chimerix is eligible to receive up to approximately $20 million in clinical, regulatory and initial commercial milestones in the United States and Europe, as well as royalties and additional milestones based on commercial sales in those territories.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMRX:US $38.26 USD -0.63

CMRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr210.50 DKK +1.00
Bioporto A/S kr1.79 DKK -0.02
Emergent Biosolutions Inc $28.39 USD -0.52
GlaxoSmithKline PLC 1,500 GBp +11.50
Novartis AG SFr.85.50 CHF +1.20
View Industry Companies
 

Industry Analysis

CMRX

Industry Average

Valuation CMRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 364.5x
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 351.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHIMERIX INC, please visit www.chimerix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.